Q1 2025 Iovance Biotherapeutics Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Transcript 10-Q8-K

Key Points

Positve

Iovance Biotherapeutics Inc (IOVA) reported over $210 million in revenue from the US launch of its cell therapy, Antagy, in its first year.
The company has activated 70 Advanced Treatment Centers (ATCs) and is preparing to onboard more, indicating a strong network expansion strategy.
Iovance Biotherapeutics Inc (IOVA) anticipates potential approvals for Antagy in the UK, Canada, and the EU, expanding its international market presence.
The company maintains a strong cash position of approximately $366 million, sufficient to fund operations into the second half of 2026.
Iovance Biotherapeutics Inc (IOVA) is on track to report updated data from its registrational trial in non-small cell lung cancer, indicating progress in its clinical pipeline.

Negative

First quarter revenue was lower than expected due to manufacturing disruptions and patient drop-offs.
The company revised its full-year revenue guidance to $250-$300 million, indicating a more conservative outlook.
Manufacturing success rates were lower in the first quarter, impacting cost of goods and gross margin.
There is a disconnect between initial target physicians and community oncologists regarding Antagy's treatment sequencing, affecting adoption.
Annual maintenance at the manufacturing facility reduced capacity by more than 50% for about a month, impacting production.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IOVA.OQ - Iovance Biotherapeutics Inc
Q1 2025 Iovance Biotherapeutics Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the IOvan Biotherapeutics 1st quarter 2025 Financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Sarah Pellegrino, SVP, IR, and corporate communications. Please go ahead.

--------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.